Global Vulvodynia Treatment Drug Market By Drug Type (Local Anesthetics, Anticonvulsants, Tricyclic Antidepressants, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2019–2028
- Published date: April 2023
- Report ID: 30664
- Number of Pages: 239
Market.us announces publication of its most recently generated research report titled, “Global Treatment Drug Market by Drug type (Local Anesthetics, Anticonvulsants, Tricyclic Antidepressants, Antimicrobials, Hormone Creams, Nerve Blocks, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Drug Store), Which offers a holistic view of the global vulvodynia treatment drug market through systematic segmentation that covers every aspect of the target market.
The Global Vulvodynia Treatment Drug Market is projected to be US$ 4,390 Mn in 2018 to reach US$ 8,081 Mn by 2028 at a CAGR of 6.3%.
Vulvodynia is defined as vulvar discomfort, most often described as burning pain, occurring in the absence of relevant visible findings or a specific, clinically identifiable, neurologic disorder. Classification is based further on whether the pain is generalized or localised and whether it is provoked, unprovoked, or both. Multiple treatment options are available for Vulvodynia such as vulvar care measures, topical, oral, and injectable medications, biofeedback, physical therapy etc.trending_up Total Revenue in 2018
$ 4,390 Mntrending_up Market CAGR of the Next Ten Years
6.3%no_encryption Market Value (US$ Mn), Share (%) and Growth Rate (%) Comparison 2012-2028Purchase this report or a membership to unlock the market value (US$ Mn), share (%) and growth rate (%) comparison for this industry.
no_encryption Leading Companies Financial HighlightsPurchase this report or a membership to unlock the leading companies financial highlights for this industry.trending_up Market Revenue of the Next Ten Years
- By Type
- By Region
- By Application
$ 8,081 Mn
Rising concern and awareness about health among women – A large number of women across the globe suffer from a variety of sexual and reproductive disorders. A few decades ago, females used to hesitate and used to avoid taking the treatment. However, owing to the rising level of education, awareness and health concerns, women these days opt for proper treatment. Therefore, the market for Vulvodynia treatment drugs is expected to grow.
Advancement in healthcare infrastructure – Vulvodynia is a pain in the vulvar region, without any specific cause. Moreover, this lack of knowledge about the cause of the disease restricted the growth of the Vulvodynia treatment market. However, the recent advancements in the healthcare industry in developed, as well as emerging economies, is anticipated to aid the growth of Vulvodynia treatment drug market.
Global Vulvodynia Treatment Drug Market Revenue (US$ Mn), 2018–2028
However, the lack of proper diagnosis is expected to hamper the market growth. Vulvodynia is not a kind of infection, and the exact cause of vulvodynia is still a subject of study. That’s why it gets difficult for the healthcare providers to diagnose the disease properly, and many women have to stay away from the treatment owing to the lack of diagnosis of the disease. This is expected to restrict the growth of the market.
Global vulvodynia treatment drug market is segmented on the basis of drug type, distribution channel and region. On the basis of drug type, the market is segmented into local anaesthetics, anticonvulsants, tricyclic antidepressants, antimicrobials, hormone creams, nerve blocks and others. Anticonvulsants segment accounts for majority share, followed by tricyclic antidepressants segment while the nerve block segment is expected to register the highest growth rate over the forecast period. On the basis of the distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online pharmacy and drug store. On the distribution channel, hospital pharmacy accounts for the majority share in the global vulvodynia treatment drug market.
Global Vulvodynia Treatment Drug Market by Drug Type, 2018
On the basis of region, the market is segmented into North America, Latin America, Western Europe, Eastern Europe, Japan, Asia-Pacific and Middle-East Africa. North America accounts for the majority share in the global vulvodynia treatment drug market, owing to favourable reimbursement policies for vulvodynia treatment drugs. Asia-Pacific is expected to register the highest growth rate over the forecast period. Countries and regions such as Japan, Latin America, Eastern Europe and Middle-East Africa are expected to register stable growth over the forecast period.
The research report on the global vulvodynia treatment drug market includes profiles of some major companies such as Pfizer Inc., Sanofi, Johnson & Johnson, AstraZeneca PLC, Eli Lilly and Company, Hisamitsu Pharmaceutical Co., Inc.
Key Market Segments
- Local Anesthetics
- Tricyclic Antidepressants
- Hormone Creams
- Nerve Blocks
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Drug Store
Key Market Players included in the report:
- Pfizer Inc.
- Johnson & Johnson
- AstraZeneca PLC
- Eli Lilly and Company
- Hisamitsu Pharmaceutical Co.Inc
For the Vulvodynia Treatment Drug Market research study, the following years have been considered to estimate the market size:
Attribute Report Details
Short Term Projection Year
Long Term Projection Year
Competitive Landscape, Revenue analysis, Company Share Analysis, Manufacturers Analysis, Volume by Manufacturers, Key Segments, Key company analysis, Market Trends, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis, strategy for existing players to grab maximum market share, and more.
North America, Europe, Asia-Pacific, South America, Middle East & Africa
United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa
| Single User|
USD / per unit
| Multi User|
USD / per unit
| Corporate User|
USD / per unit
|Report Library Access|
|Data Set (Excel)|
|Company Profile Library Access|
|Free Custumization||No||up to 10 hrs work||up to 30 hrs work|
|Accessibility||1 User||2-5 User||Unlimited|
|Analyst Support||up to 20 hrs||up to 40 hrs||up to 50 hrs|
|Benefit||Up to 20% off on next purchase||Up to 25% off on next purchase||Up to 30% off on next purchase|
|Buy Now ($ 3,499)||Buy Now ($ 4,299)||Buy Now ($ 4,999)|